Beata Lecka-Czernik

Summary

Affiliation: University of Toledo
Country: USA

Publications

  1. pmc Marrow fat metabolism is linked to the systemic energy metabolism
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, University of Toledo Health Sciences Campus, Toledo, OH 43614, USA
    Bone 50:534-9. 2012
  2. ncbi request reprint Bone as a target of type 2 diabetes treatment
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, University of Toledo Medical Center, Center for Diabetes and Endocrine Research, Toledo, OH 43614, USA
    Curr Opin Investig Drugs 10:1085-90. 2009
  3. ncbi request reprint Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus
    Beata Lecka-Czernik
    University of Toledo, College of Medicine, Department of Orthopaedic Surgery, 3000 Arlington Avenue, Toledo, OH 43614, USA
    IDrugs 13:793-801. 2010
  4. pmc Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, OH, 43614, USA
    Curr Osteoporos Rep 8:178-84. 2010
  5. doi request reprint PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism
    Beata Lecka-Czernik
    Departments of Orthopaedic Surgery and Physiology and Pharmacology, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH, 43614, USA
    Curr Osteoporos Rep 8:84-90. 2010
  6. pmc Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton
    Sima Rahman
    Departments of Orthopaedic Surgery, University ofToledo Health Sciences Campus, Toledo, OH 43614, USA
    Endocrinology 154:2687-701. 2013
  7. doi request reprint Polycaprolactone nanofiber interspersed collagen type-I scaffold for bone regeneration: a unique injectable osteogenic scaffold
    Nuray Baylan
    Department of Bioengineering, College of Engineering, University of Toledo, Toledo, OH 43606, USA
    Biomed Mater 8:045011. 2013
  8. doi request reprint Peroxisome proliferator-activated receptor delta agonist attenuates nicotine suppression effect on human mesenchymal stem cell-derived osteogenesis and involves increased expression of heme oxygenase-1
    Dong Hyun Kim
    Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA
    J Bone Miner Metab 31:44-52. 2013
  9. pmc β-catenin directly sequesters adipocytic and insulin sensitizing activities but not osteoblastic activity of PPARγ2 in marrow mesenchymal stem cells
    Sima Rahman
    Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America
    PLoS ONE 7:e51746. 2012
  10. pmc Skeletal aging and the adipocyte program: New insights from an "old" molecule
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, Toledo, Ohio, USA
    Cell Cycle 9:3648-54. 2010

Collaborators

  • Beata Lecka Czernik
  • BEATA ANNA LECKA CZERNIK
  • Sima Rahman
  • Nuray Baylan
  • Samerna Bhat
  • Dong Hyun Kim
  • Piotr J Czernik
  • Yalin Lu
  • Maggie Ditto
  • Eda Yildirim-Ayan
  • Sven Enerback
  • Stephen J Peterson
  • Joseph G Lawrence
  • Clifford J Rosen
  • Gregory Benedict
  • Nabil A Ebraheim
  • Jiayong Liu
  • Bruce E Heck

Detail Information

Publications10

  1. pmc Marrow fat metabolism is linked to the systemic energy metabolism
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, University of Toledo Health Sciences Campus, Toledo, OH 43614, USA
    Bone 50:534-9. 2012
    ..These functions may include a role in bone energy maintenance and endocrine activities to serve osteogenesis during bone remodeling and bone healing...
  2. ncbi request reprint Bone as a target of type 2 diabetes treatment
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, University of Toledo Medical Center, Center for Diabetes and Endocrine Research, Toledo, OH 43614, USA
    Curr Opin Investig Drugs 10:1085-90. 2009
    ..In summary, bone is a target of certain antidiabetic therapies and, therefore, caution is necessary in the choice of treatment for patients who are at risk of skeletal complications...
  3. ncbi request reprint Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus
    Beata Lecka-Czernik
    University of Toledo, College of Medicine, Department of Orthopaedic Surgery, 3000 Arlington Avenue, Toledo, OH 43614, USA
    IDrugs 13:793-801. 2010
    ..A phase III clinical trial was also ongoing in patients with T2DM who had recently experienced a cardiac event...
  4. pmc Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, OH, 43614, USA
    Curr Osteoporos Rep 8:178-84. 2010
    ..We also suggest a possible orthopedic complication, not yet supported by clinical studies, of delayed fracture healing in T2DM patients on TZD therapy...
  5. doi request reprint PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism
    Beata Lecka-Czernik
    Departments of Orthopaedic Surgery and Physiology and Pharmacology, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH, 43614, USA
    Curr Osteoporos Rep 8:84-90. 2010
    ..We also discuss the role of bone fat in modulation of bone marrow microenvironment and its possible contribution to the systemic regulation of energy metabolism...
  6. pmc Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton
    Sima Rahman
    Departments of Orthopaedic Surgery, University ofToledo Health Sciences Campus, Toledo, OH 43614, USA
    Endocrinology 154:2687-701. 2013
    ..Conversely, CM derived from cells overexpressing IGFBP2 or WNT10b restored osteoblastic activity in recipient cells. In conclusion, beige fat secretes endocrine/paracrine activity that is beneficial for the skeleton...
  7. doi request reprint Polycaprolactone nanofiber interspersed collagen type-I scaffold for bone regeneration: a unique injectable osteogenic scaffold
    Nuray Baylan
    Department of Bioengineering, College of Engineering, University of Toledo, Toledo, OH 43606, USA
    Biomed Mater 8:045011. 2013
    ....
  8. doi request reprint Peroxisome proliferator-activated receptor delta agonist attenuates nicotine suppression effect on human mesenchymal stem cell-derived osteogenesis and involves increased expression of heme oxygenase-1
    Dong Hyun Kim
    Department of Physiology and Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA
    J Bone Miner Metab 31:44-52. 2013
    ..This offers insight into both how nicotine affects bone remodeling and a therapeutic approach to prevent fracture and osteoporosis in smokers...
  9. pmc β-catenin directly sequesters adipocytic and insulin sensitizing activities but not osteoblastic activity of PPARγ2 in marrow mesenchymal stem cells
    Sima Rahman
    Department of Orthopaedic Surgery, University of Toledo College of Medicine, Toledo, Ohio, United States of America
    PLoS ONE 7:e51746. 2012
    ..In conclusion, β-catenin and PPARγ2 are in cross-talk which results in sequestration of pro-adipocytic and insulin sensitizing activity. The anti-osteoblastic activity of PPARγ2 is independent of this interaction...
  10. pmc Skeletal aging and the adipocyte program: New insights from an "old" molecule
    Beata Lecka-Czernik
    Department of Orthopaedic Surgery, Center for Diabetes and Endocrine Research, University of Toledo Medical Center, Toledo, Ohio, USA
    Cell Cycle 9:3648-54. 2010
    ..In this Extra View we discuss the interactive role of three molecules, PPARγ, nocturnin and IGF-I in regulating stem cell fate in the marrow and the potential implications of this network for understanding cellular aging...

Research Grants10

  1. Bone loss with aging occurs due to increased PPAR-g activity in marrow stem cells
    Beata Lecka Czernik; Fiscal Year: 2006
    ..Completion of the above aims should enable us to determine the role of PPARg in this process and will allow designing therapeutic interventions that will selectively block PPARg anti-osteoblastic activity. ..
  2. PPAR gamma-2 expression in marrow stroma during aging
    Beata Lecka Czernik; Fiscal Year: 2005
    ..Such intervention may slow down or even prevent age-related bone loss. ..
  3. Bone loss with aging occurs due to increased PPAR-g activity in marrow stem cells
    BEATA ANNA LECKA CZERNIK; Fiscal Year: 2010
    ..Completion of the above aims should enable us to determine the role of PPARg in this process and will allow designing therapeutic interventions that will selectively block PPARg anti-osteoblastic activity. ..